Indias GLP1 market has already crossed Rs 1,000 crore in annualised sales, led by Novo Nordisks semaglutide portfolio and a rapid surge in Eli Lillys Mounjaro, underscoring the scale of demand Indian generic drugmakers are preparing to tap post2026
Acta (BBA) - Mol
El glucagn sirve de contrapeso a la insulina
GLP-1 RAs, with their high costs, temporary benefits, and serious risks, fall far short of being a reliable solution
Acknowledgments The authors would like to thank SHRM, and particularly SHRM Tennessee and SHRM Austin, as well as the Midwest Business Group on Health, the NC Business Coalition on Health, and The Alliance for their assistance in organizing the focus groups
The narrative surrounding off-brand semaglutide and tirzepatide use is beginning to shift as tirzepatide was removed from the FDAs drug shortage list in December and semaglutide was taken off the list in February